(VIANEWS) – Alamo Group (ALG), Incyte Corporation (INCY), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Alamo Group (ALG)

19% sales growth and 9.74% return on equity

Alamo Group Inc. designs, manufactures, distributes, and services agricultural and infrastructure maintenance equipment for governmental and industrial use worldwide.

Alamo Group’s sales growth this year is expected to be 15% and 6.2% for next year.

Year-on-year quarterly revenue growth declined by 1%, now sitting on 1.16B for the twelve trailing months.

Volume

Today’s last reported volume for Alamo Group is 19854 which is 35.61% below its average volume of 30837.

Alamo Group’s sales growth for the next quarter is 19%. The company’s growth estimates for the present quarter and the next is 37.7% and 20.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.74%.

Volatility

Alamo Group’s last day, last week, and last month’s current volatility was 0.04%, 0.86%, and 1.25%, respectively.

Alamo Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.50% (day), 2.30% (last week), and 2.06% (last month), respectively.

Alamo Group’s Stock Yearly Top and Bottom Value

Alamo Group’s stock is valued at $154.39 at 06:22 EST, below its 52-week high of $165.98 and way higher than its 52-week low of $97.52.

Alamo Group’s Moving Average

Alamo Group’s value is above its 50-day moving average of $148.32 and above its 200-day moving average of $153.04.

2. Incyte Corporation (INCY)

18.6% sales growth and 12.79% return on equity

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States.

Incyte Corporation’s sales growth this year is anticipated to be 6.6% and 21.3% for next year.

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 2.72B for the twelve trailing months.

Volume

Today’s last reported volume for Incyte Corporation is 1141350 which is 6.26% below its average volume of 1217660.

Incyte Corporation’s sales growth for the next quarter is 18.6%. The company’s growth estimates for the current quarter and the next is a negative 40.3% and 213%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.79%.

Volatility

Incyte Corporation’s last day, last week, and last month’s current volatility was 6.99%, 3.55%, and 1.40%, respectively.

Incyte Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.14% (day), 2.57% (last week), and 2.11% (last month), respectively.

Incyte Corporation’s Stock Yearly Top and Bottom Value

Incyte Corporation’s stock is valued at $71.12 at 06:22 EST, way under its 52-week high of $101.47 and higher than its 52-week low of $71.06.

Incyte Corporation’s Moving Average

Incyte Corporation’s value is below its 50-day moving average of $75.86 and way under its 200-day moving average of $80.47.

3. Catalyst Pharmaceuticals (CPRX)

18% sales growth and 49.72% return on equity

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals’s sales growth this year is expected to be 14.1% and 20.3% for next year.

Year-on-year quarterly revenue growth grew by 22.8%, now sitting on 126.9M for the twelve trailing months.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 846977 which is 12.19% below its average volume of 964559.

Catalyst Pharmaceuticals’s sales growth is a negative 0% for the ongoing quarter and 18% for the next. The company’s growth estimates for the current quarter and the next is 11.1% and negative -75.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.72%.

Volatility

Catalyst Pharmaceuticals’s last day, last week, and last month’s current volatility was 4.19%, 1.79%, and 1.87%, respectively.

Catalyst Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.19% (day), 3.42% (last week), and 3.68% (last month), respectively.

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $5.01 at 06:22 EST, way under its 52-week high of $6.24 and way above its 52-week low of $2.88.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is way below its 50-day moving average of $5.62 and below its 200-day moving average of $5.10.

4. M/I Homes (MHO)

12.4% sales growth and 27.03% return on equity

M/I Homes, Inc., together with its subsidiaries, operates as a builder of single-family homes in Ohio, Indiana, Illinois, Michigan, Minnesota, North Carolina, Florida, and Texas, the United States.

M/I Homes’s sales growth this year is expected to be 26.1% and 6.9% for next year.

Year-on-year quarterly revenue growth grew by 34.6%, now sitting on 3.54B for the twelve trailing months.

Volume

Today’s last reported volume for M/I Homes is 334725 which is 16.14% above its average volume of 288196.

M/I Homes’s sales growth for the next quarter is 12.4%. The company’s growth estimates for the current quarter and the next is 38.2% and 18.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.03%.

Volatility

M/I Homes’s last day, last week, and last month’s current volatility was 1.16%, 2.05%, and 1.78%, respectively.

M/I Homes’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.95% (day), 2.90% (last week), and 3.26% (last month), respectively.

M/I Homes’s Stock Yearly Top and Bottom Value

M/I Homes’s stock is valued at $65.64 at 06:22 EST, way under its 52-week high of $74.85 and way above its 52-week low of $40.24.

M/I Homes’s Moving Average

M/I Homes’s value is higher than its 50-day moving average of $62.59 and above its 200-day moving average of $61.30.

5. EMCOR Group (EME)

11.8% sales growth and 16.02% return on equity

EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services in the United States.

EMCOR Group’s sales growth this year is expected to be 8.2% and 4.8% for next year.

Year-on-year quarterly revenue growth grew by 21%, now sitting on 9.22B for the twelve trailing months.

Volume

Today’s last reported volume for EMCOR Group is 10257 which is 95.64% below its average volume of 235600.

EMCOR Group’s sales growth for the next quarter is 11.8%. The company’s growth estimates for the present quarter and the next is 9.7% and 0.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.02%.

Volatility

EMCOR Group’s last day, last week, and last month’s current volatility was 0.21%, 0.94%, and 1.03%, respectively.

EMCOR Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.92% (day), 2.05% (last week), and 2.02% (last month), respectively.

EMCOR Group’s Stock Yearly Top and Bottom Value

EMCOR Group’s stock is valued at $121.83 at 06:22 EST, below its 52-week high of $129.45 and way higher than its 52-week low of $63.69.

EMCOR Group’s Moving Average

EMCOR Group’s worth is higher than its 50-day moving average of $120.72 and above its 200-day moving average of $118.36.

6. The Ensign Group (ENSG)

10% sales growth and 23.07% return on equity

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses.

The Ensign Group’s sales growth this year is expected to be 9.2% and 8.4% for next year.

Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 2.49B for the twelve trailing months.

Volume

Today’s last reported volume for The Ensign Group is 166984 which is 10.23% below its average volume of 186017.

The Ensign Group’s sales growth for the next quarter is 10%. The company’s growth estimates for the present quarter and the next is 15.4% and 18.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.07%.

Volatility

The Ensign Group’s last day, last week, and last month’s current volatility was 0.35%, 0.90%, and 1.07%, respectively.

The Ensign Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.81% (day), 2.05% (last week), and 2.19% (last month), respectively.

The Ensign Group’s Stock Yearly Top and Bottom Value

The Ensign Group’s stock is valued at $81.05 at 06:22 EST, way under its 52-week high of $98.66 and way higher than its 52-week low of $52.89.

The Ensign Group’s Moving Average

The Ensign Group’s value is under its 50-day moving average of $83.27 and under its 200-day moving average of $85.93.

7. Xylem (XYL)

8% sales growth and 10.51% return on equity

Xylem Inc. engages in the design, manufacture, and servicing of engineered products and solutions for the water and wastewater applications in the United States, Europe, the Asia Pacific, and internationally.

Xylem’s sales growth this year is expected to be 10.4% and 6.2% for next year.

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 5.01B for the twelve trailing months.

Volume

Today’s last reported volume for Xylem is 548653 which is 32.71% below its average volume of 815387.

Xylem’s sales growth for the next quarter is 8%. The company’s growth estimates for the present quarter and the next is 55% and 3.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.51%.

Volatility

Xylem’s last day, last week, and last month’s current volatility was 0.57%, 0.62%, and 0.69%, respectively.

Xylem’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.10% (day), 1.33% (last week), and 1.31% (last month), respectively.

Xylem’s Stock Yearly Top and Bottom Value

Xylem’s stock is valued at $134.34 at 06:22 EST, higher than its 52-week high of $125.25.

Xylem’s Moving Average

Xylem’s value is way above its 50-day moving average of $119.10 and way above its 200-day moving average of $109.66.

Previous days news about Xylem(XYL)

  • Take the plunge with philippe cousteau, jr.'s earthecho international and xylem watermark and join the movement for A clean water future this September. According to Business Insider on Wednesday, 8 September, "These events include beach cleanups, connecting with boy and girl scouts, implementing virtual class visits to present on water quality and collaborating with EarthEcho partners including Xylem Watermark to facilitate in-person water monitoring events near their local waterways.", "In celebration of World Water Monitoring Day on September 18, 2021, EarthEcho International is partnering with Xylem Watermark to host events nationwide and offering a suite of take-action resources at www.monitorwater.org to help communities around the world be part of a clean water future for our planet. "

LEAVE A REPLY

Please enter your comment!
Please enter your name here